Estudo randomizado de fase 2 | Adição de nintedanibe ou placebo à gentacitabina e cisplatina neoadjuvante no câncer de bexiga com invasão muscular localmente avançado.

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial – The Lancet Oncology

Comentário no Twitter

In the phase II NEOBLADE trial in 120 pts with locally advanced MIBC, addition of the multitarget RTK TKI nindetanib to neoadjuvant chemotherapy did not significantly improve the pCR rate: 37% versus 32% (OR 1.25, 70% CI 0.84–1.87; P=0.28): https://t.co/m9NXouhOcZ #blcsm

— NatureRevClinOncol (@NatRevClinOncol) April 22, 2022